Back

Classical macrophage polarisation is limited by human β-defensin 3 via an autocrine IL-4 dependent process.

Candela, M. E.; Allsop, D. J. P.; Carter, R. N.; Semple, F.; Kilanowski, F.; Webb, S.; Taggart, D.; Mullan, H. J. W.; McHugh, B. J.; Dockrell, D. H.; Davidson, D. J.; Allen, J. E.; Jenkins, S. J.; Morton, N. M.; Dorin, J. R.

2021-05-06 immunology
10.1101/2021.05.06.442606 bioRxiv
Show abstract

Human {beta}-defensin 3 (HBD3), is an anti-microbial host-defence peptide, that can rapidly enter macrophages to modulate TLR4 responses to lipopolysaccharide. However, the molecular mechanisms by which HBD3 exerts this anti-inflammatory influence remain unclear. Here, we show mice deleted for the orthologue of HBD3 have an increased acute lipopolysaccharide response in vivo. Furthermore, we found that HBD3 limited the response of macrophages to classical activation, and contemporaneously drove expression of IL-4. An increase in markers of alternative activation, and a change in metabolic flux was also observed. Consistent with these results, HBD3 enhanced the IL-4 mediated polarisation of naive macrophages. Finally, we demonstrate that the ability of HBD3 to limit macrophage classical activation requires IL-4R. These data reveal a previously unrecognised role for HBD3 in influencing the polarisation state of macrophages to enable a state conducive for repair and resolution. SYNOPSIS O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=131 SRC="FIGDIR/small/442606v2_ufig1.gif" ALT="Figure 1"> View larger version (25K): org.highwire.dtl.DTLVardef@f81c9aorg.highwire.dtl.DTLVardef@11dca23org.highwire.dtl.DTLVardef@c1e241org.highwire.dtl.DTLVardef@ed46ed_HPS_FORMAT_FIGEXP M_FIG C_FIG The anti-microbial host-defence peptide, Human {beta}-defensin 3 (HBD3), is shown here to modulate the inflammatory response to classical activation by promoting alternative activation through IL-4R, to enable a state conducive for repair and resolution. O_LIKnockout mice for the orthologous gene for HBD3, demonstrate increased acute lipopolysaccharide inflammatory response. C_LIO_LIHBD3 limited the classical activation of macrophages polarised with LPS/IFN{gamma} and drove expression of IL-4. Cells also displayed increase in alternative activation markers and promotion of oxidative phosphorylation. C_LIO_LIHBD3 enhanced the IL-4-mediated activation of naive macrophages. C_LIO_LIThe ability of HBD3 to limit macrophage classical activation and contemporaneously promote alternative activation required IL-4R. C_LI

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Frontiers in Immunology
638 papers in training set
Top 0.1%
45.2%
2
eLife
5828 papers in training set
Top 10%
9.7%
50% of probability mass above
3
Discovery Immunology
11 papers in training set
Top 0.1%
4.8%
4
The Journal of Immunology
166 papers in training set
Top 0.8%
4.0%
5
European Journal of Immunology
60 papers in training set
Top 0.4%
3.2%
6
Life Science Alliance
285 papers in training set
Top 2%
2.4%
7
Journal of Leukocyte Biology
42 papers in training set
Top 0.3%
2.4%
8
Journal of Cell Science
393 papers in training set
Top 2%
2.1%
9
iScience
1154 papers in training set
Top 13%
2.1%
10
Immunology
28 papers in training set
Top 0.2%
1.9%
11
Cell Reports
1498 papers in training set
Top 19%
1.7%
12
EMBO Reports
263 papers in training set
Top 3%
1.7%
13
International Journal of Molecular Sciences
494 papers in training set
Top 12%
1.1%
14
Cellular and Molecular Life Sciences
96 papers in training set
Top 1%
1.1%
15
Brain, Behavior, & Immunity - Health
28 papers in training set
Top 0.4%
1.0%
16
Scientific Reports
3612 papers in training set
Top 70%
1.0%
17
International Immunopharmacology
15 papers in training set
Top 0.3%
1.0%
18
Brain, Behavior, and Immunity
116 papers in training set
Top 2%
0.8%
19
Frontiers in Cellular and Infection Microbiology
109 papers in training set
Top 4%
0.8%
20
PLOS ONE
5266 papers in training set
Top 62%
0.8%
21
Nature Communications
5641 papers in training set
Top 57%
0.8%
22
ImmunoHorizons
24 papers in training set
Top 0.7%
0.6%